SEP
BMRN icon

Signature Equity Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Signature Equity Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401 Hold
7
– – ﹤0.01% 1444
2026
Q1 		$395 Hold
7
– – ﹤0.01% 1408
2025
Q4 		$416 Buy
+7
New +$381 ﹤0.01% 1549

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Signature Equity Partners's BMRN Position: Q2 2026 in Review

Signature Equity Partners held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 7 shares worth $401. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Signature Equity Partners first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $416 in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Signature Equity Partners held 7 shares of BioMarin Pharmaceuticals worth $401 as of Q2 2026.
  • Signature Equity Partners left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1444 holding.
  • Signature Equity Partners first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's BioMarin Pharmaceuticals position peaked at $416 in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.